18.09.2024 OeAW and Boehringer Ingelheim Foundation establish new Institute for biomedical artificial intelligence in Viennamore
18.09.2024 Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canadamore
18.09.2024 F2G Announces $100 Million Financing to Advance Late-Stage Development and Commercialization of Novel Antifungal Drug Candidate Olorofim in the USmore
17.09.2024 Nationales Referenzzentrum für postvirale Syndrome wird an der MedUni Wien eingerichtetmore
17.09.2024 CEBINA and Charles River Laboratories announce strategic collaboration to accelerate cutting edge neuroscience research into innovative therapeutics in the DanubeNeuro programmore
17.09.2024 Universität Wien: An Unexpected Result: The Mammalian Inner Ear is a Striking Example of Convergent evolutionmore
13.09.2024 Valneva Announces the Success of its Private Placement Raising approximately €60 Millionmore
12.09.2024 FFG FORUM 2024: „20 Jahre Zukunft: Perspektiven für den Innovationsstandort Österreich“more
11.09.2024 MedUni Vienna: Prostate cancer - New AI model can prevent unnecessary prostate removalsmore
10.09.2024 Austrian LEAD Study: LBG präsentiert neueste Ergebnisse von Österreichs größter Gesundheitsstudiemore